

# ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## COMMUNICATION

## Reaction between a haemoglobin model compound and hydrosulphide in aqueous solution†

Cite this: DOI: 10.1039/x0xx00000x

Kenji Watanabe,<sup>a,\*</sup> Toshikane Suzuki,<sup>b</sup> Hiroaki Kitagishi,<sup>b</sup> Koji Kano<sup>b,\*</sup>Received 00th January 2012,  
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

**The reaction between hydrosulphide (SH<sup>-</sup>) and a haemoglobin model, composed of a Fe(III)-porphyrin and a cyclodextrin dimer possessing a pyridine-linker (met-hemoCD3), was studied. Met-hemoCD3 formed a stable (SH<sup>-</sup>)-met-hemoCD3 complex in oxygen-free neutral aqueous solution. In the presence of O<sub>2</sub>, reversible ligand exchange between (SH<sup>-</sup>)-met-hemoCD3 (Fe(III)) and O<sub>2</sub>-hemoCD3 (Fe(II)) occurred.**

In biological systems, hydrogen sulphide (H<sub>2</sub>S; p*K*<sub>a</sub> = 6.8) is produced by the action of several enzymes such as cystathionine β-synthase, cystathionine γ-lyase, and 3-mercaptopyruvate sulphurtransferase, which utilise L-cysteine or L-homocysteine as substrates.<sup>1</sup> Although the quantity of H<sub>2</sub>S produced in the mammalian body is small (<10 ppm), H<sub>2</sub>S plays an important role in the regulation of signal transmission.<sup>2</sup> The biological function of H<sub>2</sub>S has been the focus of intense research, along with other gaseous signalling molecules such as carbon monoxide (CO) and nitric oxide (NO).<sup>2</sup> When a large amount of H<sub>2</sub>S (>700 ppm) is inhaled from the environment, some of the excess H<sub>2</sub>S is rapidly decomposed in the blood. However, when the amount of H<sub>2</sub>S inhaled exceeds the threshold limit of blood, H<sub>2</sub>S inhibits the enzymatic activity of cytochrome *c* oxidase (CC<sub>ox</sub>), a member of the respiratory chain in the mitochondria, through binding to Fe(II) in CC<sub>ox</sub>. Thus, H<sub>2</sub>S is highly toxic for living organisms.<sup>3</sup> Collman et al. studied the reaction between H<sub>2</sub>S and a synthetic CC<sub>ox</sub> model, composed of a picket fence-type Fe(II)-porphyrin

attached to a Cu(I)-triimidazole moiety, in buffered aqueous solution (pH 7).<sup>4</sup> Their results revealed that H<sub>2</sub>S reduces Fe(III) of CC<sub>ox</sub> and binds to Fe(II), therefore inhibits the catalytic activity of CC<sub>ox</sub> by displacing molecular oxygen (O<sub>2</sub>).

H<sub>2</sub>S also binds to Fe(III) metmyoglobin (metMb) and methaemoglobin (metHb), with a binding constant (*K*) of 5 × 10<sup>4</sup> M<sup>-1</sup>.<sup>5</sup> *Lucina pectinata*, a type of clam inhabiting sulphide-rich environments, expresses monomeric metHbI. This monomeric form exhibits higher binding affinity towards H<sub>2</sub>S than mammalian metHb.<sup>6</sup> In metHbI, the distal histidine (His) residue of metHb is replaced by a glutamine (Glu) residue, which stabilises the H<sub>2</sub>S complex. However, various other factors are also involved in determining the stability of the H<sub>2</sub>S complex.<sup>7,8</sup> Moreover, when H<sub>2</sub>S and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), which is generated under conditions of oxidative stress, coexist, the sulphur (S) atom is inserted into haeme.<sup>9</sup> This sulphur insertion is proposed to be mediated by the reaction between the •SH radical and the oxo-ferryl (Fe<sup>IV</sup>=O) complex, which is produced by the reaction of haeme with reactive oxygen species.<sup>10</sup>

Therefore, investigating the reactions between a simple haeme model compound with the defined structure and H<sub>2</sub>S might provide insights into the complex reactivity of haemoproteins with H<sub>2</sub>S. Several research groups have studied the reactions between synthetic porphyrins and H<sub>2</sub>S.<sup>11-16</sup> However, there is much room for investigating coordination of hydrosulphide to an Hb model compound while simultaneously considering the effects of the axial ligand and the solvent.

Our group has extensively studied 1:1 inclusion complexes of a water-soluble Fe-porphyrin and methylated β-cyclodextrin dimers linked via various bridges having nitrogenous ligands (hemoCDs), which exhibit haemoprotein-like functions in aqueous solution.<sup>17-22</sup> Met-hemoCD3 is the 1:1 inclusion complex of meso-tetrakis(4-sulfonatophenyl)porphyrinatoiron(III) (Fe(III)TPPS) and Py3OCD. Py3OCD is the per-*O*-methylated β-cyclodextrin dimer linked to a OCH<sub>2</sub>PyCH<sub>2</sub>O (Py: pyridine-3,5-


<sup>a</sup> Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan. E-mail: kwatanabe@phar.kyushu-u.ac.jp

<sup>b</sup> Department of Molecular Chemistry and Biochemistry, Faculty of Science and Engineering, Doshisha University, Kyotanabe, Kyoto 610-0321, Japan. E-mail: kojikano1223@gmail.com

† Electronic supplementary information (ESI) available: Details of experimental methods, supplementary Fig. S1–S4. See DOI: xxxxxx

diyl) bridge at the 3- and 3'-positions of the glucopyranose units (ESI†).<sup>22</sup> The structure of met-hemoCD3 was determined by X-ray crystallography, which revealed that the Fe-porphyrin moiety is completely buried within the cyclodextrin moiety and is axially coordinated by the pyridine ligand.<sup>22</sup> Because the hydrophobic environment of the cyclodextrin pores surrounds the Fe-porphyrin neighbourhood, hemoCD3 forms a stable Fe(II)-O<sub>2</sub> complex. In general, the Fe(II)-O<sub>2</sub> bond is easily oxidised by the nucleophilic attack of a water molecule.<sup>17</sup> The hemoCDs in the ferrous states reversibly bind O<sub>2</sub>, CO, and NO,<sup>18,20</sup> whereas those in the ferric states (met-hemoCDs) bind inorganic anions such as N<sub>3</sub><sup>-</sup> and CN<sup>-</sup> in aqueous solution.<sup>18,22</sup> In addition, met-hemoCDs possess peroxidase-like functions.<sup>23-25</sup> These results suggest that met-hemoCD3, a convenient haemeprotein model, binds SH<sup>-</sup> in the same way as metHb.

In this study, NaSH was used as the source of SH<sup>-</sup>. The electronic structure and reactivity of met-hemoCD3 in the presence of NaSH were studied by EPR. A high spin signal<sup>26</sup> due to met-hemoCD3 at *g* = 6.23 in oxygen-free phosphate buffer (pH 6) at 77 K disappeared upon addition of NaSH (1–2 eq.), and new characteristic signals at *g* = 2.48, 2.40, 2.26, and 1.94, ascribed to six-coordinated low-spin (SH<sup>-</sup>)-met-hemoCD3, appeared (Fig. 1,



**Fig. 1** EPR spectra of met-hemoCD3 ( $5 \times 10^{-4}$  M) in the absence (A) and presence of 1 eq. (B) and 2 eq. (C) of NaSH in phosphate buffer at pH 6 and 77 K. (D) EPR spectrum of O<sub>2</sub>-hemoCD3 ( $5 \times 10^{-4}$  M) upon addition of 3 eq. NaSH.


A–C). In contrast, addition of NaSH to the Fe(III)TPPS/(TMe- $\beta$ -CD)<sub>2</sub> complex (Fig. S1, ESI†; TMe- $\beta$ -CD: heptakis(2,3,6-tri-*O*-methyl)- $\beta$ -cyclodextrin), which does not possess the axial nitrogenous ligand, caused the disappearance of the EPR signals, indicating that a diamagnetic Fe(II) species was produced through the reduction of Fe(III) with SH<sup>-</sup>. These results suggest that the axial pyridine ligand is essential for the formation of a stable Fe(III)-(SH<sup>-</sup>) complex.

The formation constants (*K*) of (SH<sup>-</sup>)-met-hemoCD3 at various pHs were determined by UV-Vis titration (Table 1; Fig. S2, ESI†). Because OH<sup>-</sup> competes with SH<sup>-</sup> to bind to Fe(III),


**Table 1** Formation constants (*K*) of (SH<sup>-</sup>)-met-hemoCD3, determined by titration at 25 °C.

pH	<i>K</i> / M <sup>-1</sup>
6	$3.1 \times 10^5$
7	$9.6 \times 10^4$
8	$2.5 \times 10^5$
9	$7.1 \times 10^3$
10	$2.8 \times 10^3$

the *K* value of (SH<sup>-</sup>)-met-hemoCD3 decreased at higher pH. Conversely, at neutral pH (pH 6–8), the *K* values for (SH<sup>-</sup>)-met-hemoCD3 were considerably high ( $10^4$ – $10^5$  M<sup>-1</sup>; Table 1). The (SH<sup>-</sup>)-met-hemoCD3 complex shows relatively high reactivity in the reduction of Fe(II)-hemoCD3 (Fig. S3, ESI†). When CO, a strong coordinating ligand of Fe(II), was introduced into the (SH<sup>-</sup>)-met-hemoCD3 system, rapid formation of CO-hemoCD<sup>22</sup> was observed (Fig. S4, ESI†). These results suggest that homolysis of the Fe–S bond occurred, followed by insertion of CO [eqn. (1)]:




Interestingly, the EPR spectrum of Fe(II)-hemoCD3 did not change upon addition of NaSH (3 eq.), while the addition of NaSH (3 eq.) to O<sub>2</sub>-hemoCD3 ( $5.0 \times 10^{-4}$  M) generated EPR signals at *g* = 2.48, 2.39, 2.26, and 1.94, ascribed to (SH<sup>-</sup>)-met-hemoCD3 (Fig. 1D). These results indicate that SH<sup>-</sup> does not react with Fe(II)-hemoCD3, while, in the case of O<sub>2</sub>-hemoCD3, ligand exchange of O<sub>2</sub><sup>-</sup> with SH<sup>-</sup> and oxidation to Fe(III) occur spontaneously, resulting in the formation of (SH<sup>-</sup>)-met-hemoCD3 [eqn. (2)]:




When a solution of (SH<sup>-</sup>)-met-hemoCD3, prepared by the addition of 10 eq. of NaSH to met-hemoCD3 ( $5.0 \times 10^{-4}$  M), was diluted to  $5.0 \times 10^{-6}$  M in air-saturated phosphate-buffered solution (pH 6),  $\lambda_{\text{max}}$  at 422 nm, attributable to O<sub>2</sub>-hemoCD3, immediately appeared (Fig. 2), suggesting that (SH<sup>-</sup>)-met-

hemoCD3 was converted to O<sub>2</sub>-hemoCD3 by the excess O<sub>2</sub> in the medium.



**Fig. 2** Progressive absorption spectral changes of O<sub>2</sub>-hemoCD3 ( $5 \times 10^{-6}$  M) in the presence of 10 eq. NaSH in air-saturated phosphate buffer at pH 6.0 and 25°C.

Subsequently, a gradual shift of  $\lambda_{\max}$  at 398–422 nm, which was ascribed to autoxidation of O<sub>2</sub>-hemoCD3 to met-hemoCD3, was observed. The absorption spectrum of the final product showed that the autoxidation was not quantitative, and decomposition of Fe-porphyrin occurred (Fig. 2). The half-life ( $t_{1/2}$ ) of O<sub>2</sub>-hemoCD3 (autoxidation to met-hemoCD3) in the absence of NaSH at pH 7 is 51 h. However, in the presence of excess NaSH (10 eq.) at pH 6, autoxidation was accelerated ( $t_{1/2} = 10$  h), along with partial decomposition of Fe-porphyrin. Because O<sub>2</sub>-hemoCD3 reacts with SH<sup>-</sup>, reversible ligand exchange between SH<sup>-</sup> and O<sub>2</sub> (O<sub>2</sub><sup>-</sup>) generates •SH radicals and reactive oxygen species. Subsequently, these species may react with Fe-porphyrin and accelerate autoxidation [eqn. (3)]:



In summary, we found that hemoCD3 reacts with H<sub>2</sub>S. Met-hemoCD3 yields a stable (SH<sup>-</sup>)-met-hemoCD3 complex in oxygen-free aqueous solution. An Fe(III)-(SH<sup>-</sup>) complex is generated from Fe(II)-O<sub>2</sub> as a result of ligand exchange between O<sub>2</sub><sup>-</sup> and SH<sup>-</sup>. In the presence of excess O<sub>2</sub>, homolysis of the Fe(III)-S bond occurs and the Fe(II)-O<sub>2</sub> adduct is generated, along with partial decomposition of Fe-porphyrin. These findings imply that Hb catalytically mediates one-electron transfer from SH<sup>-</sup> to O<sub>2</sub> and degrades H<sub>2</sub>S *in vivo*. To the best of our knowledge, this is the first study to demonstrate the reversible reaction between SH<sup>-</sup> and the O<sub>2</sub> adduct of the synthetic haeme model in aqueous solution.

KW acknowledges JSPS Grant-in-Aid for Young Scientists (B) Grant Numbers, 25810106.

## Notes and references

- S. Singh and R. Banerjee, *Biochim. Biophys. Acta, Proteins Proteomics*, 2011, **1814**, 1518–1527.
- B. D. Paul and S. H. Snyder, *Nat. Rev. Mol. Cell Biol.*, 2012, **13**, 499–507.
- D. C. Dorman, F. J. M. Moulin, B. E. McManus, K. C. Mahle, R. A. James and M. F. Struve, *Toxicol. Sci.*, 2002, **65**, 18–25.
- J. P. Collman, S. Ghosh, A. Dey and R. A. Decreau, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 22090–22095.
- D. W. Kraus and J. B. Wittenberg, *J. Biol. Chem.*, 1990, **265**, 16043–16053.
- M. Rizzi, J. B. Wittenberg, A. Coda, M. Fasano, P. Ascenzi and M. Bolognesi, *J. Mol. Biol.*, 1994, **244**, 86–99.
- R. Pietri, A. Lewis, R. G. Leon, G. Casabona, L. Kiger, S.-R. Yeh, S. Fernandez-Alberti, M. C. Marden, C. L. Cadilla and J. Lopez-Garriga, *Biochemistry*, 2009, **48**, 4881–4894.
- C. Ramos-Alvarez, B.-K. Yoo, R. Pietri, I. Lamarre, J.-L. Martin, J. Lopez-Garriga and M. Negrerie, *Biochemistry*, 2013, **52**, 7007–7021.
- T. Shimizu, *Curr. Chem. Biol.*, 2013, **7**, 207–212.
- B. B. Rios-Gonzalez, E. M. Roman-Morales, R. Pietri and J. Lopez-Garriga, *J. Inorg. Biochem.*, 2014, **133**, 78–86.
- J. W. Pavlik, B. C. Noll, A. G. Oliver, C. E. Schulz and W. R. Scheidt, *Inorg. Chem.*, 2010, **49**, 1017–1026.
- J. A. Bennett, M. A. Neiswonger, C. D. Wheeler, J. E. Pander, III and S. E. McKinney, *J. Electrochem. Soc.*, 2012, **159**, 119–124.
- J. L. Miljkovic, I. Kenkel, I. Ivanovic-Burmazovic and M. R. Filipovic, *Angew. Chem. Int. Ed.*, 2013, **52**, 12061–12064.
- Y. Ma, H. Su, X. Kuang, X. Li, T. Zhang and B. Tang, *Anal. Chem.*, 2014, **86**, 11459–11463.
- M. D. Hartle, S. K. Sommer, S. R. Dietrich and M. D. Pluth, *Inorg. Chem.*, 2014, **53**, 7800–7802.
- S. A. Bieza, F. Boubeta, A. Feis, G. Smulevich, D. A. Estrin, L. Boechi, S. E. Bari, *Inorg. Chem.*, 2015, **54**, pp 527–533
- K. Kano, H. Kitagishi, M. Kodera and S. Hirota, *Angew. Chem. Int. Ed.*, 2005, **44**, 435–438.
- K. Kano, H. Kitagishi, C. Dagallier, M. Kodera, T. Matsuo, T. Hayashi, Y. Hisaeda and S. Hirota, *Inorg. Chem.*, 2006, **45**, 4448–4460.
- K. Kano, H. Kitagishi, T. Mabuchi, M. Kodera and S. Hirota, *Chem. Asian J.*, 2006, **1**, 358–366.
- K. Kano, Y. Itoh, H. Kitagishi, T. Hayashi and S. Hirota, *J. Am. Chem. Soc.*, 2008, **130**, 8006–8015.
- K. Kano, S. Chimoto, M. Tamaki, Y. Itoh and H. Kitagishi, *Dalton Trans.*, 2012, **41**, 453–461.
- K. Watanabe, H. Kitagishi and K. Kano, *Angew. Chem. Int. Ed.*, 2013, **52**, 6894–6897.
- H. Kitagishi, M. Tamaki, T. Ueda, S. Hirota, T. Ohta, Y. Naruta and K. Kano, *J. Am. Chem. Soc.*, 2010, **132**, 16730–16732.
- T. Ueda, S. Kumeda, H. Kitagishi and K. Kano, *Chem. Lett.*, 2013, **42**, 1366–1368.
- T. Ueda, H. Kitagishi and K. Kano, *Inorg. Chem.*, 2014, **53**, 543–551.
- R. Weiss, A. Gold and J. Turner, *Chem. Rev.*, 2006, **106**, 2550–2579.